New real-time PCR-based method for in vitro susceptibility testing of Anaplasma phagocytophilum against antimicrobial agents

International Journal of Antimicrobial Agents

Volumn 23, Issue 6, 2004, Pages 563-571

  Hunfeld, Klaus Peter ^a,b   Bittner, Thomas ^a   Rödel, Rebecca ^a   Brade, Volker ^a   Cinatl, Jindrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anaplasma phagocytophilum; In vitro susceptibility; Microdilution assay; PCR; Standardised antibiotic assay

Indexed keywords

OXACILLIN; PSEUDOMONIC ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

AMPICILLIN; ANAPLASMA PHAGOCYTOPHILUM; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; AZITHROMYCIN; DNA, BACTERIAL; DNA, RIBOSOMAL; DOXYCYCLINE; GENES, RRNA; GENTAMICINS; KETOLIDES; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; QUINOLINES; REPRODUCIBILITY OF RESULTS; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S; SENSITIVITY AND SPECIFICITY;

EID: 2942546246     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.02.019     Document Type: Article

References (21)

1. Sood SK, Dumler JS. Human E. equi/E. phagocytophila (EEP) infection on Long Island. In: Program and Abstracts of the 35th Infectious Disease Society of America Meeting, San Francisco, CA; 1997 [abstract 67].
2. Lotric-Furlan S., Petrovec M., Avsic-Zupank T., et al. Human ehrlichiosis in Central Europe. Wien Klien Wochenschr. 110:1998;894-897
3. Bakken JS, Dumler JS. Ehrlichiosis. In: Cunha BA, editor. Tick-borne infectious diseases. Diagnosis and management. New York, Basel: Marcel Dekker Inc.; 1999. p. 142-3.
4. Woessner R., Gaertner B.C., Grauer M.T., et al. Incidence and prevalence of infection with human granulocytic ehrlichiosis agent in Germany. A prospective study in young healthy subjects. Infection. 29:2001;271-273
5. Buitrago M.I., Ijdo J.W., Rinaudo P., et al. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin. Infect. Dis. 27:1998;213-215
6. Goodman J.L., Nelson C., Vitale B., Madigan J.E., Dumler J.S., Munderloh U.G. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. N Engl. J. Med. 334:1996;209-215
7. Horowitz H.W., Hsieh T.C., Aguero-Rosenfeld M.E., et al. Antimicrobial susceptibility of Ehrlichia phagocytophila. Antimicrob. Agents Chemother. 45:2001;786-788
8. Hunfeld KP. Contributions to seroepidemiology, diagnostics, and antimicrobial susceptibility of borrelia, ehrlichia and babesia as indigenous tick-borne pathogens. Habilitationsschrift. Johann Wolfgang Goethe- Universität; June 2003. p. 210-6.
9. Hunfeld K.P., Kraiczy P., Wichelhaus T.A., Schäfer V., Brade V. New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur. J. Clin. Microbiol. Infect. Dis. 19:2000;27-32
10. Lohmann C.P., Linde H.J., Reischl U. Improved detection of microorganisms by PCR in delayed endophthalmitis after cataract surgery. Ophtalmology. 107:2000;1047-1051
11. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; 11th informational supplement. NCCLS document M100-S11. Wayne, PA, USA: NCCLS; 2001.
12. Betzel G., Seller M., Eichner C. Reproducibility of PCR on the LightCycler system. Biochemica. 1:2000;22-26
13. Klein M.B., Nelson C.M., Goodman J.L. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Antimicrob. Agents. Chemother. 41:1997;76-79
14. Maurin M., Bakken J.S., Dumler J.S. Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States. Antimicrob. Agents Chemother. 47:2003;413-415
15. Simon C, Stille W. Antibiotika-Therapie in Klinik und Praxis, 10, Neubearbeitete und erweiterte Auflage. Stuttgart, New York: Schattauer Verlag; 2000.
16. Boerner J., Failing K., Wittenbrink M.M. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: influence of test conditions on minimal inhibitory concentration (MIC) values. Zentralb. Bakteriol. 283:1995;49-60
17. Hunfeld K.P., Wichelhaus T.A., Rödel R., Acker G., Brade V., Kraiczy P. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi. Antimicrob. Agents Chemother. 48:2004;344-347
18. Hunfeld K.P., Kraiczy P., Kekoukh E., Schäfer V., Brade V. Standardised in vitro susceptibility testing of Borrelia burgdorferi against well-known and newly developed antimicrobial agents - possible implications for new therapeutic approaches to Lyme disease. Int. J. Med. Microbiol. 291(Suppl. 33):2002;125-137
19. Roth A, Mauch H, Göbel UB. Quality standards in microbiological diagnostics - Nucleic acid amplification techniques. 2nd revised ed. Stuttgart, Munich, New York: Urban & Fischer; 2001. ISBN: 3-437-41590-5.
20. Brennan R.E., Sanuel J.E. Evaluation of Coxiella burnettii antibiotic susceptibilities by real-time PCR assay. J. Clin. Microbiol. 41:2003;1869-1874
21. Fenollar F., Maurin M., Raoult D. Wolbachia pipientis growth kinetics and susceptibilities to 13 antibiotics determined by immunoflourescence staining and real-time PCR. Antimicrob. Agents Chemother. 47:2003;1665-1671